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Abstract
Background: Gabapentin is an antiepileptic drug used in a variety of chronic pain conditions.
Increasing numbers of randomized trials indicate that gabapentin is effective as a postoperative
analgesic. This procedure-specific systematic review aims to analyse the 24-hour postoperative
effect of gabapentin on acute pain in adults.
Methods: Medline, The Cochrane Library and Google Scholar were searched for double-blind
randomized placebo controlled trials of gabapentin for postoperative pain relief compared with
placebo, in adults undergoing a surgical procedure.
Qualitative analysis of postoperative effectiveness was evaluated by assessment of significant
difference (P < 0.05) in pain relief using consumption of supplemental analgesic and pain scores
between study groups.
Quantitative analyses of combined data from similar procedures, were performed by calculating the
weighted mean difference (WMD) of 24-hour cumulated opioid requirements, and the WMD for
visual analogue scale (VAS) pain, (early (6 h) and late (24 h) postoperatively), between study groups.
Side-effects (nausea, vomiting, dizziness and sedation) were extracted for calculation of their
relative risk (RR).
Results: Twenty-three trials with 1529 patients were included. In 12 of 16 studies with data on
postoperative opioid requirement, the reported 24-hour opioid consumption was significantly
reduced with gabapentin. Quantitative analysis of five trials in abdominal hysterectomy showed a
significant reduction in morphine consumption (WMD – 13 mg, 95% confidence interval (CI) -19
to -8 mg), and in early pain scores at rest (WMD – 11 mm on the VAS, 95% CI -12 to -2 mm) and
during activity (WMD -8 mm on the VAS; 95% CI -13 to -3 mm), favouring gabapentin. In spinal
surgery, (4 trials), analyses demonstrated a significant reduction in morphine consumption (WMD
of – 31 mg (95%CI – 53 to -10 mg) and pain scores, early (WMD – 17 mm on the VAS; 95 % CI -
31 to -3 mm) and late (WMD -12 mm on the VAS; 95% CI -23 to -1 mm) also favouring gabapentin
treatment. Nausea was improved with gabapentin in abdominal hysterectomy (RR 0.7; 95 % CI 0.5
to 0.9). Other side-effects were unaffected.
Conclusion: Perioperative use of gabapentin has a significant 24-hour opioid sparing effect and
improves pain score for both abdominal hysterectomy and spinal surgery. Nausea may be reduced
in abdominal hysterectomy.
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Background
Prevention and treatment of postoperative pain and com-
plications such as nausea and vomiting, continues to be a
major challenge in postoperative care and plays an impor-
tant role in the early mobilization and well-being of the
surgical patient. Opioid analgesics, with their well-known
side-effects, continues to represent a cornerstone in post-
operative pain control, and testing new analgesics as well
as combinations of analgesics in order to reduce the need
for opioids, is a key area in acute pain research. [1]
Gabapentin, an anti-epileptic drug that has demonstrated
analgesic effect in both diabetic neuropathy, post-herpetic
neuralgia and neuropathic pain [2-4], affects the nocicep-
tive process by binding to the α2δ subunit of voltage
dependent calcium channels [5]. In pain models it has
shown anti-hyperalgesic properties, possibly by reducing
central sensitization, a prerequisite for postoperative
hyperalgesia, and gabapentin, together with dextrometh-
orphan and ketamine, represents a new option in postop-
erative pain care, which recently has been the subject of
intensive research.
An increasing number of randomized trials indicate that
gabapentin is effective as an postoperative analgesic. Until
now, four meta-analyses with pooled data from rather few
studies (7, 8, 12 and 16 trials, respectively) [6-9], demon-
strates that gabapentin displays an effect on both postop-
erative pain score and opioid usage. In these meta-
analyses, data from studies with very different surgical
interventions are pooled and therefore the effect in a par-
ticular surgical setting is difficult to predict. We find that
the recent number of publications allows a more proce-
dure-specific systematic review in this area, which is the
purpose of this paper.
Methods
Search strategy
Relevant randomized controlled trials were identified by
performing a Medline [10], a Cochrane Library [11] and a
Google Scholar search [12], without language restrictions.
Free text combinations including the search terms:
"gabapentin", "post-operative pain" and "post-operative
analgesia" were used [see Additional file 1]. Additional
papers where sought by reviewing the reference list of
retrieved reports and relevant reviews. Last search was per-
formed January 2007. The QOURUM guidelines for
reporting meta-analyses were followed [13].
Study selection criteria
Reports were considered if they were double-blind, rand-
omized controlled trials of gabapentin (experimental
intervention group) for postoperative pain relief com-
pared with placebo (control intervention group) in adult
patients (> 18 years) undergoing a surgical procedure.
Only studies, in which data on either pain (visual ana-
logue scale (VAS) or verbal score (VRS)) or supplemental
postoperative analgesic consumption were stated, were
included. Studies with less than 10 patients in treatment
arms were not included [14].
Assessment of quality
Each identified study was read and scored independently
by two authors (OM + JBD), using a 5-point scoring sys-
tem as described by Jadad et al [15]. If the reports were
described as randomized, one point was given. One point
was added if the randomization was described and appro-
priate (random number of tables, computer generated,
etc), and likewise one point was subtracted if the rand-
omization was described and inappropriate. If the study
was described as double-blind one point was given, and
an additional point was added if the method of blinding
was described and appropriate. (identical placebo, active
placebo etc.) For inappropriate blinding one point was
subtracted. Finally a point was given if withdrawals and
dropouts were appropriately described. Disagreement
between the authors was solved through discussion.
Extraction of data
Data from the studies were extracted onto a datasheet by
one of the authors (OM). This included type of surgery;
number of patients in intervention and control groups;
time of administration and regimen of gabapentin treat-
ment; mean VAS pain scores at rest and during mobiliza-
tion early (at 4 or 6 hours) and late (at 24 hours) after
surgery; supplemental analgesic regimen; type of and
amount of supplemental analgesic consumption; and
possible side-effects (nausea, vomiting, dizziness and
sedation). Side-effects reported as somnolence or drowsi-
ness were grouped under sedation, and reports of light-
headedness and vertigo were grouped under dizziness.
Pain reported on a 0 – 10 scale was converted to a 0 – 100
scale. In dose-finding studies, we extracted data from each
dose-group onto the data sheet. When data in a study was
only shown graphically, we extracted data from graphs.
We contacted eight authors to get supplemental data for
analysis, and received requested information from all.
Qualitative analysis
Qualitative analysis of postoperative effectiveness was
evaluated by assessment of significant difference (P < 0.05
as reported in the original paper) in pain relief using con-
sumption of supplemental analgesic and pain scores
between study groups, and by an assessment of clinical
importance of observed findings. In addition, internal
sensitivity was evaluated by an assessment of pain scores.
It has been recognised that adequate sensitivity in trials of
analgesics for acute pain, may only be achieved when
patients are experiencing at least moderate pain (VAS pain
score > 30 mm) with placebo, as it is difficult to detect an
improvement with a low degree of pain [16,17].BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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Quantitative analysis
Quantitative analyses of combined data were only per-
formed with data from similar procedures (e.g. hysterec-
tomy), but not across trials with different surgical
procedures.
Quantitative analyses of combined data from similar pro-
cedures were performed by calculation of the weighted
mean difference (WMD) of the 24-hour cumulated opioid
use between study group, and by calculation of WMD of
VAS pain scores between study groups early (4 – 6 h) and
late (24 h) after surgery, whenever sufficient data were
provided in original papers (e.g. standard deviation (SD),
number of included patients in each study group and the
relevant mean value).
Opioids other than morphine were converted to their
morphine equivalents, based on the equivalence of 100
µg fentanyl, 5 mg ketobemidone, and 100 mg tramadol
respectively to 10 mg morphine.
Side-effects
From papers where data were available, dichotomous data
were extracted for calculation of the relative risk (RR) of
side-effects (nausea, vomiting, dizziness and sedation).
Statistical software
Quantitative analyses were performed using the Review
Manager (RevMan) software (version 4.2 for Windows,
Copenhagen, The Nordic Cochrane Centre, The Cochrane
Collaboration, 2003). A random effect model was used if
the statistical test for heterogeneity was positive, and a
fixed effect model if the test came out negative.
Results
Our Medline and Cochrane Library search revealed 28 rel-
evant randomized trials published in the period from
2001 to 2006. One additional paper was identified by the
Google Scholar search, giving a total of 29 relevant trials.
All trials were published in English.
Six trials were subsequently excluded. One [18] was only
published in abstract form, one [19] had only 9 patients
in the gabapentin treatment arm, one [20] addressed only
chronic postoperative pain, and in two trials [21,22],
gabapentin was part of a multimodal regimen in the treat-
ment group, which was tested against placebo only.
Finally, in one trial [23] oxazepam was used instead of
placebo in the control group.
Thus, data from 23 trials including a total of 1529
patients, of which 810 received gabapentin were included.
One trial [24] tested four different dosing regimens of
gabapentin versus placebo, one trial [25] tested two differ-
ent dosing regimens versus placebo, and one [26] com-
pared gabapentin administered before with after incision
and placebo. Accordingly, 28 comparisons were per-
formed in the 23 included trials.
Characteristics of included trials
An overview of the included trials is presented in Table 1.
The retrieved studies were generally of high quality
(median quality score: 5; range 1 – 5).
The surgical procedures were abdominal hysterectomy in
five studies [27-31], spinal surgery in four studies [24,32-
34], breast surgery in two studies [35,36] and a variety of
different surgical procedures in the remaining twelve stud-
ies [25,26,37-46]. Median number of patients included in
the studies was 50 (range 40 – 306). Three studies
[25,35,38]lasted for only 4 h postoperatively, and one
study [34] for 8 hours. The remaining studies lasted for 24
hours or longer.
Gabapentin dosing
In most studies gabapentin was administered one to two
hours preoperatively, but in three studies [31,34,36] a
multiple (repeat) dosing regimen initiated the day before
surgery was investigated.
In sixteen studies a single dose of gabapentin, varying
from 300 mg to 1200 mg was administered and in seven
studies [27,30,31,34,36,39,46] repeat dosing regimens
were investigated. (Table 1)
Postoperative analgesic effect: a qualitative overview
Supplemental opioid consumption
Supplemental analgesia was in fourteen trials adminis-
tered as intravenous patient controlled analgesia (PCA),
in four studies [32,36,37,46] on a demand basis, and in
three studies [42,44,45] according to a VAS score. One
study [43] used patient controlled epidural analgesia
(PCEA) and finally in one study [41], the postoperative
medication was administrated at home by the patient.
Morphine was used as postoperative analgesic in most
studies, but four studies [24,26,32,37] used fentanyl, one
study [28] tramadol intravenously, two studies [36,41]
propoxiphen, two studies diclofenac [42,44] and one
study [46] morphine for the first 4 hours succeeded by
oral ketobemidon.
Sixteen studies provided data on 24-hour opioid con-
sumption. The 24-hour morphine or calculated morphine
equivalent usage was ranging from 4 to 99 mg in the treat-
ment groups, and from 6 to 122 mg in the placebo groups,
with a large variation between surgical procedures (Table
1).B
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Table 1: Included, randomized, double-blind, controlled studies of gabapentin in postoperative pain.
Reference Quality 
Score
Surgical 
procedure
η gabapentin/
placebo
Gabapentin dosing & 
administration
Analgesic and delivery Effect on analgesic 
consumption (24 hours)
Effect on pain score 
at rest (6 h)
Effect on pain score 
at rest (24 h)
Side-effects
Dierking 2004 [27] 5 Abdominal 
hysterectomy
39/32 1200 mg 1 h pre-op. + 600 
mg × 3
PCA – morphine Morphine reduced from 63 
to 43 mg
NS NS NS
Turan 2004a [28] 5 Abdominal 
hysterectomy
25/25 1200 mg 1 h pre-op. PCA – tramadol 
intravenously
Tramadol reduced from 420 
to 270 mg
VAS lower with 
gabapentin (P = 0.000)
VAS lower with 
gabapentin (P = 0.000)
NS
Gilron 2004 [30] 5 Abdominal 
hysterectomy
23/24 600 mg 1 h pre-op. + 600 
mg × 2
PCA -morphine Morphine reduced from 82 
to 57 mg
VAS lower with 
gabapentin (P < 0.001)
VAS lower with 
gabapentin (P < 0.02)
Sedation increased 
with gabapentin
Turan 2006a [29] 5 Abdominal 
hysterectomy
25/25 1200 mg 1 h pre-op. PCA -morphine Morphine reduced from 53 
to 41 mg
VAS lower with 
gabapentin (P < 0.01)
VAS lower with 
gabapentin (P < 0.05)
NS
Fassoulaki 2006 [31] 3 Abdominal 
hysterectomy
25/28 400 mg × 4 initiated day 
before surgery
PCA – morphine Morphine reduced from 26 
to 20 mg
NS NS
Pandey 2004a [32] 4 Lumbar 
discoidectomy
28/28 300 mg 2 h pre-op. Fentanyl on demand Fentanyl reduced from 360 
to 234 ug
VAS lower with 
gabapentin (P < 0.05)
VAS lower with 
gabapentin (P < 0.05)
NS
Pandey 2005a [24] 5 Lumbar 
discoidectomy
4 × 20/20 300–600–900–1200 mg 2 
h pre-op. (4 diff. groups)
PCA-fentanyl Fentanyl reduced from 1218 
to 627–988 ug
VAS lower with 
gabapentin (P < 0.05)
VAS lower with 
gabapentin (P < 0.05)
NS
Turan 2004b [33] 5 Lumbar 
discoidectomy or 
spinal fusion
25/25 1200 mg 1 h pre-op. PCA-morphine Morphine reduced from 43 
to 16 mg
VAS lower with 
gabapentin. (P < 0.01)
NS Vomiting reduced 
with gabapentin
Radhakrishnan 2005 [34] 4 Lumbar 
discoidectomy/
laminectomy
30/30 400 mg night before 
surgery + 400 mg 2 h pre-
op.
PCA-morphine (study 
lasted for 8 h)
NS (study lasted for 8 h) NS NS
Dirks 2002 [35] 5 Radical 
mastectomy
31/34 1200 mg 1 h preop. PCA-morphine (study 
lasted for 4 h)
Morphine reduced from 29 
to 15 mg
VAS lower with 
gabapentin (P < 0.018)
NS
Fassoulaki 2002 [36] 4 Matectomy or 
lumpectomy with 
axillary dissection
22/24 400 mg × 3 starting the 
evening before surgery
On demand. 
(Propoxyphene & 
paracetamol given i.m.)
NS NS NS NS
Pandey 2005b [26] 5 Nefrectomy 2 × 20/20 Pre-incision (2 h pre-op.)/
post-incision groups. 600 
mg in both.
PCA-fentanyl Fentanyl reduced from 925 
to 563 ug/624 ug
VAS lower with 
gabapentin in both 
groups (P < 0.05)
VAS lower with 
gabapentin in both 
groups (P < 0.05)
NS
Bartholdy 2006 [38] 5 Laparascopic 
sterilization
38/38 1200 mg 1/2 h pre-op. PCA-morphine (Study 
lasted for 4 h)
NS NS NS NS
Pandey 2004b [37] 3 Laparascopic 
chole-cystectomy
153/153 300 mg 2 h pre-op. Fentanyl on demand. Fentanyl reduced from 356 
to 221 ug
VAS lower with 
gabapentin (P < 0.05)
VAS lower with 
gabapentin (P < 0.05)
Sedation + PONV 
increased with 
gabapentin
Omran 2005 [39] 5 Pulmonal 
lobectomy
25/25 1200 mg 1 h pre-op. and 
600 mg × 2
PCA-morphine Morphine reduced from 32 
to 24 mg
VAS lower with 
gabapentin (P < 0.05)
VAS lower with 
gabapentin (P < 0.05)
NS, vomiting 
reduced with 
gabapentin
Tuncer 2005 [25] 1 Major orthopedic 
surgery
2 × 15/15 1200 – 800 mg 1 h pre-op. PCA-morphine (Study 
lasted only 4 hours)
Morphine reduced from 21 
to 11 mg/15 mg
NS NS
Menigaux 2005 [40] 5 Arthroscopic 
anterior cruciate 
ligament repair
20/20 1200 mg 1–2 h preop. PCA-morphine Morphine reduced from 48 
to 21 mg
NS NS NS
Adam 2006 [41] 5 Arthropscopic 
shoulder surgery
27/26 800 mg 2 h pre-op. Nerveblock + on demand 
paracetamol + 
propoxyphene
NS NS NS NS
Turan 2007 [42] 5 Hand surgery 20/20 1200 mg 1 h pre-op. IVRA + diclofenac 
according to VAS score
Diclofenac reduced from 63 
to 30 mg
NS NS NS
Turan 2006b [43] 5 Lower extremity 
plastic surgery
20/20 1200 mg 1 h pre-op. PCEA bolus (bupivacaine 
and fentanyl)
PCEA bolus reduced with 
gabapentin
VAS lower with 
gabapentin (P < 0.001)
NS NS, dizziness 
increased with 
gabapentin
Al-Mujadi 2006 [45] 5 Thyroid surgery 37/35 1200 mg 2 h pre-op. Morphine according to 
VAS score
Morphine reduced from 30 
to 15 mg
VAS lower with 
gabapentin (P < 0.01)
VAS lower with 
gabapentin (P < 0.01)
NS
Mikkelsen 2006 [46] 5 Tonsillectomy 22/27 1200 mg 1 h pre-op. + 600 
mg × 2
Morphine on demand + tbl. 
Ketobemidone by patient
Morphine NS. 
Ketobemidone reduced 
from 4.5 to 2.0 mg
NS NS Dizziness & 
vomiting increased 
with gabapentin
Turan 2004c [44] 5 Ear-Nose-Throat 
surgery
25/25 1200 mg 1 h pre-op. Diclofenac according to 
VAS
Diclofenac reduced from 111 
to 33 mg
VAS lower with 
gabapentin (P < = 
.001)
VAS lower with 
gabapentin (P < 0.001)
NS, dizziness 
increased with 
gabapentin
PCA, patient-controlled analgesia; NS, not significant; pre-op, pre-operatively; VAS, visual analogue scale; IVRA, intravenous regional anaesthesia; PCEA, patient-controlled epidural analgesia;BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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In 12 of the 16 studies [24,26-29,32,33,37,39,40,45,46]
opioid consumption was significantly reduced with
gabapentin compared with placebo. Opioid sparing with
gabapentin was, however, of variable clinical importance,
varying between 2 and 59 mg of morphine (Figure 1). No
obvious dose response relationship was apparent between
significant and non-significant trials with respect to opi-
oid sparing.
Two trials investigated gabapentin in a dose-response reg-
imen. Pandey et al [24] found that increasing the gabap-
entin dose above 600 mg did not significantly increase the
opioid sparing effect, and Tuncer et al [25] found no dif-
ference between 800 and 1200 mg gabapentin on mor-
phine consumption.
Pain intensity at rest
Early postoperatively
All 23 included trials reported on pain scores at rest early
after operation. In twelve [24,26,28-30,32,33,37,39,43-
45] of these 23 trials, significantly lower pain scores were
observed with gabapentin. The reduction in pain ranged
between 10 and 29 mm on the VAS score. None of the
eleven trials with no observed reduction in pain intensity
had sufficient internal sensitivity since pain scores in none
of the control groups were more than 30 mm on the VAS.
Late postoperatively
Nineteen of the included 23 studies [24,26-33,36,37,39-
46] reported on late (24 hours) pain score at rest. In ten of
these trials [24,26,28-30,32,37,39,44,45] a significantly
lower pain score, varying between a reduction of 5 and 23
mm on the VAS, was observed with gabapentin. Only one
of the trials with no observed reduction in pain intensity
had sufficient internal sensitivity.
No obvious dose response relationship was apparent
between significant and non-significant trials with respect
to late pain scores.
Pain scores during activity
Early postoperatively
Eleven trials [27-29,31,34-36,38,39,45,46] reported on
pain during activity early after operation. Five of these
[28,29,35,39,45] observed a significant reduction with
gabapentin, varying between 8 and 22 mm on the VAS.
Four [27,31,34,36] of the six trials with no observed
reduction in pain intensity had sufficient internal sensitiv-
ity.
Late postoperatively
Nine [27-31,36,39,45,46] trials reported on late pain
score during activity and four [29,30,39,45] trials
observed a significantly lower pain score with gabapentin,
varying between 6 and 21 mm on the VAS score. Three
[27,31,36] of the five trials with no observed reduction in
pain intensity had sufficient internal sensitivity.
Side-effects
Nausea
Twenty-one studies including 763 patients receiving
gabapentin reported on postoperative nausea. In twenty
of these no significant differences between study groups
were observed, however, in one study on laparoscopic
cholecystectomy [37] significantly more nausea and vom-
iting was observed in the gabapentin group.
Vomiting
Seventeen studies including 529 patients receiving gabap-
entin reported on vomiting and in 14 [24-
29,32,34,38,40,42-45] of these no differences between
groups were observed. One author found a higher [46]
incidence and two authors a significant lower [33,39] inci-
dence of vomiting with gabapentin.
Dizziness
Eighteen studies including 690 patients receiving gabap-
entin reported on this endpoint. Fourteen [24-
29,32,33,35,38,39,41,42,45] found no difference in inci-
dence between the groups. Three authors [43,44,46]
found a higher incidence in the gabapentin group, and
one [37] a higher incidence in the placebo group.
Sedation
Nineteen studies including 705 patients receiving gabap-
entin reported on the incidence of somnolence, drowsi-
ness or sedation, and seventeen [24,26-29,33-35,38-46]
found no difference between the two groups. Two authors
[30,33] found a higher incidence of sedation with gabap-
entin.
Reduction in post-operative morphine requirements with  gabapentin vs. placebo Figure 1
Reduction in post-operative morphine requirements 
with gabapentin vs. placebo. Data are calculated from 
the mean consumption of patient controlled analgesia (PCA) 
(21,23,24,25,26,27,28,30,36,37), 'on demand' administered 
analgesia (29,34) or analgesia 'administered at home by the 
patient' (43) in each study group from 0 to 24 h post-opera-
tively.
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In summary, a significant opioid-sparing effect was
observed in almost all studies reporting of cumulative
opioid consumption, which, however, was of varying
magnitude. Pain scores at rest were, although to a smaller
extent, significantly reduced with gabapentin in all studies
but one, with sufficient sensitivity to test this parameter.
Pain scores during activity were reduced in about half the
sensitive studies. Finally, no consistent difference in opi-
oid related side effects or other side effect attributable to
gabapentin was observed in this qualitative analysis.
Procedure specific results
The 23 included studies represented a variety of surgical
procedures of which more than one paper was available
for only abdominal hysterectomy [27-31] spinal surgery
(discectomy or spinal fusion surgery) [24,32-34] and mas-
tectomy [35,36]. The remaining procedures were only
evaluated in one study each.
In the following section we present quantitative analyses
from studies of hysterectomy and spinal surgery, whereas
data from studies of mastectomy did not allow for quan-
titative analyses.
Hysterectomy
Two studies administered a single dose of gabapentin pre-
operatively, and three studies used a multiple dosing reg-
imen. (For details, see Table 1).
Opioid consumption
Five trials of abdominal hysterectomy including 137
patients receiving gabapentin provided data on cumula-
tive 24-hour supplemental opioid consumption. The
combined data showed that the WMD of the 24-hour
morphine consumption was significant in favour of
gabapentin (WMD -13 mg, CI -19 to -8 mg). (Figure 2)
Pain scores
Four trials including 112 patients receiving gabapentin
provided data on early (4–6) VAS pain scores at rest.
WMD between treatment groups was significant in favour
of gabapentin (WMD -11 mm on the VAS; 95% CI -21 to
-2 mm). (Figure 3)
Meta-analysis Figure 3
Meta-analysis. Visual analogue pain (VAS) score (0–100 mm) early (4–6 h) at rest for patients in abdominal hysterectomy 
receiving gabapentin preoperatively. WMD, weighted mean difference; CI, confidence interval.
Meta-analysis Figure 2
Meta-analysis. 24 hours cumulative morphine (mg) consumption for patients in abdominal hysterectomy receiving gabapentin 
preoperatively. WMD, weighted mean difference; CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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The WMD of late (24 h) VAS pain scores between treat-
ment groups was non-significant (WMD -5 mm on the
VAS; 95% CI -12 to 2 mm). (Figure 4)
Three trials provided data on early and late pain scores
during activity respectively. The WMD of early VAS pain
score between treatment groups was significant in favour
of gabapentin (WMD -8 mm on the VAS; 95% CI -13 to -
3 mm) (Figure 5), whereas the WMD of late VAS pain
score between study groups was non-significant (WMD 0
mm on the VAS; 95% CI -4 to 3 mm) (Figure 6).
Nausea and vomiting
Four trials including 112 patients receiving gabapentin
provided data on postoperative nausea, and the com-
bined data showed that the RR was significant in favour of
gabapentin (RR 0.7; 95 % CI 0.5 to 0.9) (Figure 7). Three
trials provided data on postoperative vomiting. Calcula-
tion of the RR was non-significant (RR 0.9; 95% CI 0.6 to
1.2) (Figure 8).
Dizziness
Three trials including 89 patients receiving gabapentin
reported on the incidence of dizziness, and the combined
data showed that the RR was non-significant (RR 1.4; 95%
CI 0.9 to 2.1) (Figure 9).
Sedation
Four trials investigated the incidence of either somno-
lence or sedation, and tree trials provided data for analy-
ses. The combined data showed that the RR was non-
significant between groups (RR 2.3; 95 % CI 0.8 to 7.2)
(Figure 10).
In summary, cumulative 24-hour opioid consumption
and early pain scores were significantly reduced with
gabapentin. Nausea, but not vomiting, dizziness and
sedation, was significantly reduced with gabapentin.
Spinal surgery
Three studies administered a single dose of preoperative
gabapentin and one study a multiple doses regimen. (For
details, see Table 1)
Meta-analysis Figure 5
Meta-analysis. Visual analogue pain (VAS) score (0–100 mm) early (4–6 h) with mobilization for patients in abdominal hyster-
ectomy receiving gabapentin preoperatively. WMD, weighted mean difference; CI, confidence interval.
Meta-analysis Figure 4
Meta-analysis. Visual analogue pain (VAS) score (0–100 mm) late (24 h) at rest for patients in abdominal hysterectomy 
receiving gabapentin preoperatively. WMD, weighted mean difference; CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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Meta-analysis Figure 7
Meta-analysis. Side-effects, incidence of nausea for patients in abdominal hysterectomy receiving gabapentin preoperatively. 
RR, relative risk; CI, confidence interval.
Meta-analysis Figure 6
Meta-analysis. Visual analogue pain (VAS) score (0–100 mm) late (24 h) with mobilization for patients in abdominal hysterec-
tomy receiving gabapentin preoperatively. WMD, weighted mean difference; CI, confidence interval.
Meta-analysis Figure 8
Meta-analysis. Side-effects, incidence of vomiting for patients in abdominal hysterectomy receiving gabapentin preoperatively. 
RR, relative risk; CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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Opioid consumption
Three trials of spinal surgery including 113 patients receiv-
ing gabapentin provided data on cumulative 24-hour sup-
plemental opioid consumption. The combined data
showed that the WMD between study groups was signifi-
cant in favour of gabapentin (WMD -31 mg, 95% CI -53
to -10 mg) (Figure 11).
Pain scores
Four trials including 143 patients receiving gabapentin
provided data on early pain scores at rest, and the WMD
was significant in favour of gabapentin (WMD -17 mm on
the VAS; 95% CI -31 to -3 mm) (Figure 12).
In the same trials the WMD of late VAS pain scores at rest
was also significant in favour of gabapentin (WMD -12
mm on the VAS; 95% CI -23 to -1 mm) (Figure 13).
Pain scores during activity early after operation were only
provided in one trial [34] and found non-significant.
Nausea and vomiting
Four trials provided data on postoperative nausea and
vomiting. The combined data showed that the RR's were
non-significant (nausea: RR 0.96; 95 % CI 0.47 to 1.97;
vomiting: RR 0.51; 95 % CI 0.22 to 1.18) (Figure 14 + 15
).
Dizziness
Three trials including 133 patients receiving gabapentin
reported on the incidence of postoperative dizziness.
Combined data showed that the RR was non-significant
(RR 1.31; 95 % CI 0.6 to 3.1) (Figure 16).
Sedation
Three trials including 135 patients receiving gabapentin
provided data for the incidence of postoperative somno-
Meta-analysis Figure 9
Meta-analysis. Side-effects, incidence of dizziness for patients in abdominal hysterectomy receiving gabapentin preoperatively. 
RR, relative risk; CI, confidence interval.
Side-effects, incidence of sedation for patients in abdominal hysterectomy receiving gabapentin preoperatively Figure 10
Side-effects, incidence of sedation for patients in abdominal hysterectomy receiving gabapentin preoperatively. RR, relative risk; 
CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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Meta-analysis Figure 12
Meta-analysis. Visual analogue pain (VAS) score (0–100 mm) early (4–6 h) at rest for patients in spinal surgery receiving 
gabapentin preoperatively. WMD, weighted mean difference; CI, confidence interval.
Meta-analysis Figure 11
Meta-analysis. 24 hours cumulative morphine (mg) consumption for patients in spinal surgery receiving gabapentin preopera-
tively. WMD, weighted mean difference; CI, confidence interval.
Meta-analysis Figure 13
Meta-analysis. Visual analogue pain (VAS) score (0–100 mm) late (24 h) at rest for patients in spinal surgery receiving gabap-
entin preoperatively. WMD, weighted mean difference; CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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Meta-analysis Figure 16
Meta-analysis. Side-effects, incidence of dizziness for patients in spinal surgery receiving gabapentin preoperatively. RR, rela-
tive risk; CI, confidence interval.
Meta-analysis Figure 14
Meta-analysis. Side-effects, incidence of nausea for patients in spinal surgery receiving gabapentin preoperatively. RR, relative 
risk; CI, confidence interval.
Meta-analysis Figure 15
Meta-analysis. Side-effects, incidence of vomiting for patients in spinal surgery receiving gabapentin preoperatively. RR, rela-
tive risk; CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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lence and sedation, and combined data showed that the
RR was non-significant. (RR 1.5; 95 % CI 0.3 to 8.6). (Fig-
ure 17).
In summary, cumulative 24-hour opioid consumption,
and early and late pain intensity at rest was significantly
reduced with gabapentin. Nausea, vomiting dizziness and
sedation was not affected by gabapentin.
Discussion
This is the first systematic review with focus on procedure-
specific effects of gabapentin in postoperative pain, and
we have demonstrated that preoperative gabapentin
reduces 24-hour postoperative opioid consumption for
patients in abdominal hysterectomy and spinal surgery.
For abdominal hysterectomy pain scores at rest and dur-
ing activity were significantly improved with gabapentin
in the early but not the late postoperative phase, whereas
pain scores for patients in spinal surgery were improved at
rest both early and late. Furthermore, an improvement in
the incidence of nausea for abdominal hysterectomy
patients was demonstrated, whereas no other side-effects
(vomiting, dizziness, sedation) showed significant differ-
ences between treatment groups.
Opioid consumption
The overall 24-hour reduction in opioid consumption fol-
lowing abdominal hysterectomy as well as spinal surgery,
confirm the results from reviews with pooled data from a
variety of surgical procedures [6-9], and the postoperative
opioid sparing effect of gabapentin compared to placebo
seems unquestionable.
In our review the opioid sparing in abdominal hysterec-
tomy (13 mg morphine), is somewhat different from that
of spinal surgery (32 mg morphine), and several reasons
for this result could be thought of. First, data for spinal
surgery might have been skewed, since one trial [24] used
very high postoperative doses of fentanyl, and conse-
quently reported a larger opioid sparing effect (56 mg
morphine). If this study was removed from the analyses,
we could demonstrate a 24-hour WMD of – 20 mg mor-
phine instead. Second, the pain scores at rest for patients
in spinal surgery are higher than for abdominal hysterec-
tomy both early (mean VAS 42 mm vs. 30 mm) and late
(mean VAS 26 mm vs. 17 mm), and it is possible that the
analgesic effect of gabapentin simply reflects this differ-
ence in pain states. Third, the patho-physiology of postop-
erative pain in spinal surgery might be of a different origin
than for abdominal hysterectomy, e.g. that pre- and per-
operative nerve damage in a higher degree contributes to
postoperative pain in spinal surgery than in abdominal
hysterectomy. Gabapentin is effective in the treatment of
chronic neuropathic pain [4], and so a larger analgesic
effect in postoperative pain after spinal surgery than
abdominal hysterectomy is a possibility.
Pain score
The relevance of the pain score improvement demon-
strated in the quantitative analysis is debatable. A mini-
mal clinical significant change in patient pain severity has
previously been measured as 13 mm in trauma patients
[47,48], and another author [49] reports of a 33 % pain
intensity difference being clinically meaningful. Using
these definitions our 11 mm VAS pain relief at rest for
abdominal hysterectomy patients are of minor clinical
value, whereas the pain relief in spinal surgery patients (-
17 mm at rest early) could be of clinical importance, since
it may improve patients ability to resume daily activity.
However, comparison of pain scores during PCA treat-
ment is problematic since the patients can avoid uncon-
trolled pain in both treatment groups. Accordingly, our
primary outcome parameter was morphine consumption.
Meta-analysis Figure 17
Meta-analysis. Side-effects, incidence of sedation for patients in spinal surgery receiving gabapentin preoperatively. RR, rela-
tive risk; CI, confidence interval.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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Our analyses indicate, that preoperative gabapentin
reduces postoperative pain scores more effectively in the
early rather than the late postoperative period. Several
explanations may be possible. Most studies used a single
dose of gabapentin, and since Tmax in plasma is 2–3 h, the
plasma level of gabapentin accordingly is higher in the
early postoperative phase. One study [27] has demon-
strated a significant inverse association between plasma
levels of gabapentin and morphine usage both at two and
four hours postoperatively, indicating a dose-response
relationship. Furthermore, the postoperative pain scores
are generally higher in the early compared to the late post-
operative phase, and consequently, the improvement in
pain score by gabapentin could also be relatively larger in
this phase. Finally, the absence of internal sensitivity (VAS
< 30 mm) may also play a role in measuring the effect of
gabapentin, since five of eight trials in the two procedures
that were non-significant had low internal sensitivity.
In the most recent review [9] the authors reported of a sig-
nificant reduction in both early (6 h) and late (24 h) VAS
pain scores with a single preoperative dose of 1200 mg
gabapentin (WMD -17 mm and -11 mm, respectively).
The improvement in VAS-pain reported in the reviews by
Hurley et al [8] and Seib et al [7] also correlate well with
our findings.
Side-effects
One of the major challenges in postoperative pain treat-
ment is to combine different treatment modalities, in
order to improve patient analgesia and potentially reduce
side-effects [1]. A cornerstone in this area is to minimize
the need for postoperative opioid analgesics and hope-
fully reduce side effects, especially postoperative nausea
and vomiting (PONV). Zhao et al has reported a dose-
response relationship between opioid use and adverse
events for patients in ambulatory surgery. Every 3–4 mg
increase of morphine usage was associated with 1 addi-
tional clinically meaningful opioid-related symptom [50].
Marret et al [51] reported that the opioid sparing by
NSAID and COX-2 inhibitors (approximately 30 %) was
followed by a significant reduction in PONV and sedation
(also by approximately 30%), but not in urinary retention
and respiratory depression.
In this light it is noteworthy, that despite of the opioid
sparing effect with gabapentin, our analyses of side-effects
showed a just significant lower incidence of nausea in
favour of gabapentin for abdominal hysterectomy, but
not spinal surgery patients, while vomiting and sedation
were non-significant between treatment groups. These
disappointing results correspond with results from
another review on opioid sparing with the use of COX-2
inhibitors and the lack of evidence for reduction of opioid
related side-effects [52].
One of the reasons for this finding could be the relatively
small number of patients and thereby low statistical
power of our analyses. A post-hoc statistical power calcu-
lation of the non-significant quantitative analyses of
adverse events, using a risk of Type I error on 5% and the
observed cumulated difference between treatment groups,
revealed a statistical power of less than 50% on analyses
of most adverse events in both abdominal and spinal sur-
gery.
Another reason could be the lack of quality of data on
adverse events from the original papers, as in most reports
adverse events were not well defined and only reported as
present or absent. Furthermore, data of adverse events
were a mixture of spontaneous reporting and specific
questioning.
We did not find any sign of clinically limiting side-effect
with the use of gabapentin, and especially the data for
sedation and dizziness were non-significant. It is possible
that the well-known sedative effect of gabapentin may be
masked by the use of opioids in the studies and the fact
that we monitor patients in the early phase after general
anaesthesia.
Limitations
The wide variability of gabapentin dosing regimens, and
the differences in pain score- and side-effect evaluation,
undoubtedly influences the outcome of this review, as do
the pooling of different rescue analgesics (morphine, fen-
tanyl and tramadol). By making this review procedure
specific we tried to minimize variability in the pooled out-
come parameters, but differences in e.g. surgical tech-
niques among the different centres may still limit our
analyses.
Another important limitation for the interpretation of the
analgesic effect of gabapentin is the low VAS pain score in
many of the included trials, both early and especially 24
hour postoperatively, since previous studies has empha-
sized the importance of moderate to high initial pain
intensity in postoperative assessment of analgesic drugs
[16].
In our quantitative analysis the primary outcome is PCA
or "on demand" opioid consumption with simultaneous
VAS-pain measurement. The assumption is that patients
in the active and control treatment groups will titrate
"down" to the same low VAS-pain, and the difference in
opioid consumption at the same VAS-pain gives us the
valid difference in opioid consumption. This only hap-
pens in three of nine trials which is a limitation when the
analgesic effect of gabapentin is interpreted.BMC Anesthesiology 2007, 7:6 http://www.biomedcentral.com/1471-2253/7/6
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All trials in this review were randomized and the method-
ological quality satisfactory, the median Oxford quality
score being 5, and so selection bias should not have been
a problem. Most trials reported of a positive outcome of
either opioid reduction or pain score improvement, and
publication bias (skewed publication of only trials with a
positive outcome) cannot be ruled out. Given the nature
of abdominal hysterectomy gender bias is not the case
here, whereas for the spinal surgery trials twice as many
male patients were included as women (173 vs. 93). How-
ever, since the male/female distribution generally was
equal among treatment groups, we find no tendency to
gender bias in the trials. Language restriction to only arti-
cles published in English could be a potential bias, but we
did not find any non-English published articles. Many
analyses revealed heterogeneity among the included stud-
ies, and in these cases we used a random-effect model in
the analyses to compensate. Finally almost all studies rep-
resent small sample sizes with the increased likelihood of
Type 2 errors.
The development of chronic post surgical pain has
attracted increased attention [53] and with central sensiti-
zation as a prerequisite, gabapentin with its ability to
attenuate secondary hyperalgesia in pain models [54,55],
is an interesting "anti-hyperalgesic". Only one of the
included trials investigated pain beyond the immediate
postoperative period [31], and our review cannot make a
conclusion on this subject. In two excluded studies by Fas-
soulaki et al [21,22], gabapentin was investigated together
with local anaesthetics as part of a multimodal analgesic
regimen. In both abdominal hysterectomy and breast sur-
gery, a reduction in postoperative morphine usage, as well
as pain for more than one month postoperatively was
reported.
In the qualitative analysis of the trials we found no obvi-
ous dose-response relationship for the use of periopera-
tive gabapentin. One trial [24] investigated the effect of
different preoperative gabapentin doses (300–600–900–
1200 mg) and found no additional analgesic effect raising
the gabapentin dose above 600 mg. It is the only study in
this review addressing this subject and so, the material
does not allow for any conclusions on this topic.
In a recent pilot trial by Leung and colleagues [19], preop-
erative gabapentin significantly reduced the incidence of
postoperative delirium. This subject is sparsely addressed
in the trials covered here. Two studies reported on lack of
concentration [24,26], two studies reported on visual dis-
turbances [35,39], and one study on hallucinations [43].
All were non-significant on the subject.
Conclusion
In conclusion, the perioperative use of gabapentin has a
significant 24-hour opioid sparing effect for both abdom-
inal hysterectomy and spinal surgery patients, whereas the
reduction in pain score is more inconsistent. Nausea may
be reduced in abdominal hysterectomy. All other side-
effects were non-significant between treatment groups.
Future trials in this area should include gabapentin as part
of a multimodal postoperative treatment strategy, with
focus on both acute and chronic pain states. Pain score
during mobilisation is mandatory, and the effect of
gabapentin on postoperative delirium needs further
exploration.
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